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INTRODUCTION
Most countries predict an increase in health care costs asso-
ciated with the increasing occurrence of chronic diseases. In
fact, rising health care costs are one of the most important
social problems governments will face in the near future. Can-
cer, cardiovascular disease, cerebrovascular disorders, hyper-
tension, and diabetes mellitus are among the most common
chronic diseases around the world. In South Korea, a specific
health care system for cancer has been established by the
National Cancer Center Act, which led to the foundation of
the National Cancer Center in 2000. In contrast, national
health care policy regarding cardiovascular disease and cere-
brovascular disorders, as well as hypertension and diabetes
mellitus (both, major causal diseases for vascular diseases),
have been addressed by the National project for cardiovas-
cular and cerebrovascular disorders beginning in 2005. Dur-
ing its first term of activation (from 2005 to 2009), the con-
struction of health care  infrastructure was the main focus,
and the strategies must be prepared for the 2nd term. Studies
OBJECTIVES: To assess the association between the occurrence of cerebrovascular disorders and a medi-
cation adherence in diabetes mellitus patients.
METHODS: Medical records from 1,114 new patients with diabetes mellitus were collected and the occur-
rence of cerebrovascular disorders was observed. Data was gathered from the health examination records
of diabetes mellitus patients registered at the Korean Metabolic Syndrome Research from 1996 to 2005,
medication records from the National Health Insurance Corporation and death data from the National Statis-
tics Office from 1997 to 2007. Hazard ratios were analyzed using the Cox proportional hazard model to
test the association between the occurrence of cerebrovascular disorders and the level of medication adher-
ence. Medication adherence was calculated using Continuous measure of Medication Acquisition (CMA).
RESULTS: Of 1,114 diabetes mellitus patients, cerebrovascular disorders occurred in 67 cases (6.1%). The
mean duration for the development of a cerebrovascular disorder was 3.82 yr. Medication adherence (≥0.8
vs. <0.5: HR, 3.26; 95% CI, 1.47-7.21, ≥0.8 vs. 0.5-0.7 HR, 0.99; 95% CI, 0.33-2.95) was an independent
factor associated with the occurrence of cerebrovascular disorders in diabetes mellitus.
CONCLUSION: Increased medication adherence is necessary to prevent the occurrence of cerebrovascu-
lar disorders in diabetes mellitus patients. Furthermore we propose that CMA be considered as a method
for monitoring medication adherence in clinics.
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investigating practical methods for the management of risk
factors of cardiovascular disease and cerebrovascular disorders
would provide the evidence for the next stage of this Nation-
al project.
Despite a decrease in death rate, cerebrovascular disorders
continue to have the highest death rate in South Korea [1].
Therefore, research focusing on cerebrovascular disorders
and related factors, especially modifiable risk factors, which
can be targeted for intervention in health care programs, must
be conducted. With the exception of age, a non-modifiable
risk factor, modifiable risk factors for cerebrovascular disor-
ders include: hypertension, diabetes mellitus, smoking ciga-
rettes, alcohol consumption, and hyperlipidemia [2]. In South
Korea, of these modifiable risk factors, the prevalence and
death rate for diabetes mellitus have recently been on the in-
crease [1, 3].
Moreover, because the medication adherence rate and blood
sugar control rate remains low [3], population attributable risk
of diabetes mellitus as the causal disease for cerebrovascular
disorder occurrences is likely to increase. Hence, evaluation
of the association between the occurrence of cerebrovascular
disorders in diabetes mellitus patients and related risk factors
is necessary. In addition to known risk factors for cerebrovas-
cular disorders, medication adherence should be considered
to be a modifiable risk factor in diabetes mellitus patients. 
To date, in South Korea, no studies have been conducted
on the association between the occurrence of cerebrovascular
disorders in patients with diabetes mellitus and medication
adherence. 
The overall goal of this study is to understand the role of
medication adherence in the prevention of cerebrovascular
disorders in diabetes mellitus patients, by observing the asso-
ciation between the occurrence rate of this disorder in patients
with diabetes mellitus and the level of patient medication ad-
herence. 
MATERIALS AND METHODS
Study Population
The study population were selected from 180,720 diabetes
mellitus free individuals registered at the Korean Metabolic
Syndrome Research Center from 1996 to 2005. 
Data Collection 
I. Data for the occurrence of cerebrovascular disorders and
medication adherence was collected from the National Health
Insurance Corporation and the National Statistics Office from
1997 to 2007.
II. Risk factors for cerebrovascular disorders: Data for hyper-
tension, cigarette smoking, alcohol consumption, total choles-
terol, high-density lipoprotein (HDL), low-density lipopro-
tein (LDL), and triglyceride levels were collected from the
records of health examinations conducted before the diagno-
sis of diabetes mellitus. 
Definition of Variables 
Cerebrovascular disorder occurrences
Defined as those which resulted in death or a diagnosis of
I60-I64 according to the ICD-10, and which occurred after the
first diagnosis of diabetes mellitus. 
Medication adherence
Medication adherence was observed using the Continuous
measure of Medication Acquisition (CMA). CMA is consid-
ered to be the most appropriate measure of medication ad-
herence for chronic diseases which require continuous medi-
cation therapy over an extended period of time, such as hyper-
tension, diabetes mellitus, and mental diseases [4]. CMA is
calculated as follows: 
a. The total number of days between the first and last pre-
scriptions during the observation period is determined. 
b. From ‘a,’ the total number of days medication was dis-
pensed is summed (except the last day, which is not inclu-
ded in ‘a.’). 
c. CMA is then calculated as ‘b’ divided by ‘a’ (b/a). 
Age
Patient age at the time of diabetes mellitus diagnosis. 
Cigarette smoking
Anyone who smokes, regardless of frequency or the dura-
tion for which he or she has been smoking. 
Alcohol consumption
Anyone who consumes alcohol, regardless of the amount
of alcohol consumed or the duration for which he or she has
been drinking. 
Hypertension
For the purposes of this study, hypertension and pre-hyper-
tension (systolic BP ≥120 mmHg or diastolic BP ≥80 mmHg)
are considered to be hypertension, according to the Seventh
Report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure, JNC-7 [5].
Diabetes mellitus
Applying the standard of the American Diabetes Associa-
tion (2007), a fasting blood sugar (FBS) of 126 or higher isdefined as diabetic. 
Diabetes mellitus occurrences
Cases representing major disease, in the range of E10-E14
from ICD-10 were defined as diabetes mellitus. For this study,
criteria for diabetes mellitus occurrences were: a) Patients who
visited a physician for diabetes mellitus for the first time be-
tween 1997 and 2007, after at least one prior health exami-
nation. b) Patients with no past history of diabetes mellitus,
who had FBS levels <126 mg/dL, HbA1C levels ≤6%, and
creatinine levels ≤1.5 mg/dL, based on their most recent med-
ical examination prior to their first visit to a physician for dia-
betes mellitus. Of the patients who fulfilled criteria a) and b),
patients whose first visit to the physician for diabetes mellitus
was in the year 1997 were excluded from the study. 
Duration of observation
The observation period began with the diagnosis of diabetes
mellitus. 
Statistical Analysis
Hazard ratios (HRs) were analyzed using the Cox-propor-
tional hazard model, with cerebrovascular disorder occurren-
ces defined as ‘event’ and observation duration as ‘time’. SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA) was used for sta-
tistical data analysis. 
RESULTS
The mean time for the development of cerebrovascular dis-
order in the study population was 3.82 yr, with no differences
associated with gender, but a significant difference associated
with age (3.98 yr for patients ≤54 yr of age, and 3.64 yr for
patients ≥55 yr of age) (Table 1). 
Of the 1,114 diabetes mellitus patients included in the pre-
sent study, 67 (6.0%) were later diagnosed with cerebrovas-
cular disorders. HRs for the occurrence of cerebrovascular
disorders in diabetes mellitus patients were calculated to be
1.90 (95% CI, 1.18-3.07) for male vs. female patients, and
2.02 (95% CI, 1.22-3.33) for patients ≤54 yr old vs. patients
≥55 yr old (Table 2). 
HRs for all risk factors identified before the occurrence of
diabetes mellitus (cigarette smoking, alcohol consumption,
hypertension, total cholesterol, HDL, LDL, and triglycerides),
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Table 1. The mean duration from initial diagnosis of diabetes mel-
litus to the occurrence of a cerebrovascular disorder by sex and
age
n
(Total=
1,114)
Occurred
cases
(n=67)
HR 95% CI
Table 2. Crude hazard ratios (HRs) for the occurrence of cere-
brovascular disorders in diabetes mellitus patients versus sex
and age
Sex Male 742 33 1.00
Female 372 34 1.90 1.18-3.07
Age (yr) ≤54 569 24 1.00
≥55 545 43 2.02 1.22-3.33
n
(Total=
1,114)
Occurred
cases
(n=67)
HR 95% CI
Table 3. Crude hazard ratios (HRs) for the occurrence of cere-
brovascular disorders in diabetes mellitus patients versus mod-
ifiable risk factors
HDL, High density lipoprotein (mg/dL); male-normal ≥40, abnormal <40,
female-normal ≥50, abnormal <50; LDL, Low density lipoprotein.
Cigarette smoking
No 671 47 1.00
Yes 443 20 0.67 0.40-1.14
Alcohol drinking
No 302 24 1.00
Yes 812 43 0.75 0.45-1.23
Hypertension
No 331 17 1.00
Yes 783 50 1.14 0.66-1.98
Total cholesterol (mg/dL)
<200 523 31 1.00
≥200 591 36 1.09 0.67-1.76
HDL
Normal 730 44 1.00
Abnormal 384 23 0.91 0.55-1.51
LDL (mg/dL)
<130 696 39 1.00
≥130 418 28 1.33 0.82-2.16
Triglyceride (mg/dL)
<150 541 40 1.00
≥150 573 27 0.63 0.39-1.03
Medication adherence
≥0.8 355 7 1.00
0.5-0.7 239 6 1.01 0.34-3.01
<0.5 520 54 3.32 1.50-7.33
Sex Male 3.72 2.48 0.092
Female 4.00 2.62
Age ≤54 3.98 2.56 0.027
≥55 3.64 2.49
Total 3.82 2.53
SD, standard deviation.4
were not statistically significant (Table 3). 
Medication adherence (≥0.8 vs. <0.5: HR, 3.31; 95% CI,
1.50-7.33) and patient age (patients ≤54 yr old vs. patients
≥55 yr old: HR, 1.81; 95% CI, 1.08-3.03) were both found
to be statistically significant independent factors associated
with cerebrovascular disorder (Table 4). 
Figure 1 shows the cumulative rate of cerebrovascular dis-
order occurrences versus medication adherence. On the graph,
traces corresponding to medication adherence ≥0.8, and be-
tween 0.5-0.7 overlap and are difficult to differentiate. 
DISCUSSION
The increased occurrence of chronic diseases, which is affec-
ted by the population growth of people 65 yr of age and older,
lifestyle changes and environmental changes, is an important
issue that modern society must take seriously. In addition, the
population growth in South Korea of people aged 65 and older
is faster than in any other country, accelerating the rate at
which our society is burdened by such phenomenon. 
This burden can be significantly lessened by preparing spe-
cific plans for the prevention, treatment and rehabilitation of
major chronic diseases. Although the mortality rate from cere-
brovascular disorder is on the decrease, it still constitutes 10%
of the total causes of death, and has the highest mortality rate
among single diseases. Deaths due to diabetes mellitus (a risk
factor for cerebrovascular disorder) are also on the increase,
and currently this disease has the 6th highest mortality rate [1].
With respect to cerebrovascular disorder occurrences in
diabetes mellitus patients, for every 1% increase in HbA1C
levels, there is a 1.37 fold increase in the mortality rate [6],
whereas for every 1% decrease in HbA1C, there is a 12%
decrease in the mortality rate due to cerebral infarction [7]. 
In contrast, in patients with no past history of cerebrovas-
cular disorders, it has been reported that blood sugar level
control has no effect on the occurrence of cerebrovascular dis-
orders [8], indicating a need for further study of the association
between diabetes mellitus care and the occurrence of cere-
brovascular disorders. 
In light of this, the present study investigated the association
between medication adherence of diabetes mellitus patients
and cerebrovascular disorder occurrences. 
The mean time for the development of cerebrovascular
disorders in diabetes mellitus patients was 3.82 yr (SD 2.53
yr), with no differences associated with gender. In addition,
although the occurrence rate was not different with respect
to gender, the rate was substantially lower for patients ≤55
yr old compared to patients ≥55 yr old. In this study, absence
of a past history of diabetes mellitus was confirmed using health
examination records from before the initial diagnosis of dia-
betes mellitus, and medication data from 1997 to 2007, which
excludes any past history of diabetes mellitus before 1997.
Thus, the mean time before the development of cerebrovas-
cular disorders in diabetes mellitus patients could be underes-
timated. 
According to observations based on data from health exami-
nations conducted prior to initial diagnosis of diabetes melli-
tus, all other risk factors (cigarette smoking, alcohol consump-
tion, hypertension, total cholesterol, HDL, LDL, and triglyc-
eride levels) were found not to be associated with the occur-
rence of cerebrovascular disorders. 
In addition to being a known as a risk factor for cerebrovas-
cular disorders, diabetes mellitus is also associated with an in-
creased recurrence risk [9, 10]. Moreover, some studies have
shown that the association between diabetes mellitus and cere-
brovascular disorders differs depending on the type of cere-
brovascular disorder. For example, although diabetes melli-
tus is a risk factor for the occurrence of cerebral infarction
Epidemiology and Health 2011;33:e2011001
HR 95% CI
Table 4. Adjusted hazard ratios (HRs) for the occurrence of cer-
ebrovascular disorders in diabetes mellitus patients*
*Cox-proportional hazard model included gender, age, and medication
adherence as covariates.
Sex Male 1.00
Female 1.64 0.99-2.68
Age (yr) ≤54 1.00
≥55 1.81 1.08-3.03
Medication adherence ≥0.8 1.00
0.5-0.7 0.99 0.34-2.99
<0.5 3.31 1.50-7.33
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Figure 1. Cumulative occurrence rate of cerebrovascular disor-
der versus level of medication adherence in diabetes mellitus
patients. Medicaton adherence;          , ≥8;          , 5-7;          , <5. [11-13], whether it is a risk factor for cerebral hemorrhage is,
reportedly, unclear [12, 14]. In fact, in the present study, of
the 67 patients diagnosed with a cerebrovascular disorder, 12
patients had cerebral hemorrhages, while 50 suffered from a
cerebral infraction. However, because these two diseases are
not currently differentiated in the National health care system,
the present study analyzed overall occurrences and causes of
cerebrovascular disorders. We propose further study on the
association between diabetes mellitus and different types of
cerebrovascular disorders. 
Although the occurrence of cerebrovascular disorders in
the general population is higher in the elderly [2], in diabetes
mellitus patients younger than 55, the risk of cerebrovascular
disorder is 10 times [15]. However, in the present study, pati-
ents 55 and older were 1.81 times more likely to develop cere-
brovascular disorders than patients less than 55 yr old, sug-
gesting that additional study on the association between age
and the occurrence of cerebrovascular disorder in diabetes
mellitus patients is necessary. 
The association between blood sugar level control in dia-
betes mellitus patients and a reduced risk for cerebrovascular
disorders has yet to be clearly determined [2, 16]. 
In this study, medication adherence was used as an index
for observing the association between diabetes mellitus care
and the occurrence of cerebrovascular disorders. Although
the observation of the total days of prescription from medical
insurance data were only used in this study to measure pati-
ents’ compliance with their prescription, this data is also able
to quantitate medication adherence in clinics and therefore,
medication adherence can be used as an index to monitor dia-
betes mellitus care.
Measurement of patient compliance (medication adherence)
using refilled prescription data from the drugstore is most ap-
propriate for large scale studies using secondary data [4]. The
present study used the Continuous measure of medication
acquisition (CMA), the most appropriate measure of medica-
tion adherence in chronic diseases that require long-term med-
ication. CMA is also used in medication adherence observa-
tions by the National Health Insurance Corporation, and a
CMA of 0.8 is used as a reference for observing patient com-
pliance [17]. Because there is no nationally suggested level of
medication adherence, CMA levels of 0.8 and 0.5, in three
divisions were used in the present study. 
Hazard ratios for cerebrovascular disorder occurrences ad-
justed for gender and age were statistically significant for medi-
cation adherence ≥0.8 vs. <0.5 (HR, 3.31; 95% CI, 1.50-
7.33), but were not significant for medication adherence ≥
0.8 vs. 0.5-0.7 (HR, 0.99; 95% CI, 0.34-2.99). Therefore,
ensuring a medication adherence of at least 50% or more
may reduce the risk of cerebrovascular disorder in diabetes
mellitus patients. In the present study, there are several limi-
tations, such as the possible underestimated time elapsed be-
fore patient development of cerebrovascular disorders, and
the accuracy of diagnoses from medical insurance data, sug-
gesting that the level of medication adherence required for
preventing cerebrovascular disorders in diabetes mellitus pati-
ents is not definite. 
However, observation and control of medication adherence
based on CMA monitoring is recommended, and further study
on the level of medication adherence required for the preven-
tion of cerebrovascular disorders in diabetes mellitus patients
is suggested. 
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